A Phase 1, Open-Label, Single-Center Study Evaluating Absolute Bioavailability, Safety and Tolerability of Subcutaneous Formulation of RYI-018 Compared to Intravenous Formulation in Overweight and Obese Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs Namacimab (Primary) ; Namacimab
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Bird Rock Bio
- 29 Apr 2019 Status changed to "Completed".
- 19 Nov 2018 Status changed from not yet recruiting to recruiting.
- 19 Nov 2018 Recruitment completion is expected on 22 Nov 2018 according to Australian New Zealand Clinical Trials Registry.